Free to Read
Two-step transcriptional amplification–lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer
Yoshiyuki Hattori,
Yoshie Maitani,
Yoshiyuki Hattori
Institute of Medicinal Chemistry, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo 142-8501, Japan
Search for more papers by this authorCorresponding Author
Yoshie Maitani
1To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorYoshiyuki Hattori,
Yoshie Maitani,
Yoshiyuki Hattori
Institute of Medicinal Chemistry, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo 142-8501, Japan
Search for more papers by this authorCorresponding Author
Yoshie Maitani
1To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorAbstract
A two-step transcriptional amplification system (TSTA) was used to enhance the efficacy of suicide gene therapy for treatment of prostate cancer. We designed a TSTA system and constructed two types of plasmid: one containing GAL4–VP16 fusion protein under the control of a tumor-specific promoter, the other containing luciferase or herpes simplex virus thymidine kinase (HSV-tk) under the control of a synthetic promoter. The TSTA systems using nanoparticles based on lipids were evaluated by measuring the amount of induced luciferase activity as a function of prostate-specific membrane antigen (PSMA) and midkine (Mk) promoters, specific for LNCaP and PC-3 prostate cancer cells, respectively. In LNCaP cells that were PSMA-positive, the TSTA system featuring the PSMA enhancer and promoter exhibited activity that was 640-fold greater than a system consisting of one-step transcription with the PSMA promoter. In contrast, this difference in activity did not occur in PSMA-negative PC-3 cells. In Mk-positive PC-3 cells, the TSTA system with the Mk promoter exhibited a five-fold increase in activity over one-step transcription, but such activity was not induced in Mk-negative LNCaP cells. When using HSV-tk for suicide gene therapy, TSTA systems featuring the PSMA or Mk promoter inhibited in vitro cell growth in the presence of ganciclovir. Furthermore, the TSTA system featuring the Mk promoter suppressed in vivo growth of PC-3 tumor xenografts to a greater extent than one-step transcription. These findings show that TSTA systems can enhance PSMA and Mk promoter activities and selectively inhibit PC-3 cell growth in tumors. This suggests that TSTA systems featuring tumor-specific promoters are suitable for cancer treatment by gene therapy. (Cancer Sci 2006; 97: 787–798)
References
- 1 El Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004; 94: 1–14.
- 2 Dass CR, Burton MA. Lipoplexes and tumours. A review. J Pharm Pharmacol 1999; 51: 755–70.
- 3
Gao X,
Porter AT,
Grignon DJ,
Pontes JE,
Honn KV.
Diagnostic and prognostic markers for human prostate cancer.
Prostate
1997; 31: 264–81.
10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 4 Suzuki S, Tadakuma T, Asano T, Hayakawa M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res 2001; 61: 1276–9.
- 5 Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81–5.
- 6 Wright GL Jr, Grob BM, Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326–34.
- 7 Uchida A, O’Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001; 58: 132–9.
- 8 Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312–18.
- 9 Sekiguchi K, Yokota C, Asashima M et al. Restricted expression of Xenopus midkine gene during early development. J Biochem (Tokyo) 1995; 118: 94–100.
- 10 Tsutsui J, Kadomatsu K, Matsubara S et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res 1993; 53: 1281–5.
- 11
Garver RI Jr, Radford DM,
Donis-Keller H,
Wick MR,
Milner PG.
Midkine and pleiotrophin expression in normal and malignant breast tissue.
Cancer
1994; 74: 1584–90.
10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V PubMed Web of Science® Google Scholar
- 12 Konishi N, Nakamura M, Nakaoka S et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57: 253–7.
- 13 Yoshida Y, Tomizawa M, Bahar R et al. A promoter region of midkine gene can activate transcription of an exogenous suicide gene in human pancreatic cancer. Anticancer Res 2002; 22: 117–20.
- 14 Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol 2001; 8: S5–S8.
- 15 Segawa T, Takebayashi H, Kakehi Y, Yoshida O, Narumiya S, Kakizuka A. Prostate-specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res 1998; 58: 2282–7.
- 16 Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98: 14 595–600.
- 17 Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res 2002; 93: 1154–63.
- 18 Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 2002; 168: 2659–64.
- 19
Gschwend JE,
Fair WR,
Powell CT.
Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines.
Prostate
1997; 33: 166–76.
10.1002/(SICI)1097-0045(19971101)33:3<166::AID-PROS4>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 20 Block A, Milasinovic D, Mueller J, Schaefer P, Schaefer H, Greten H. Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors. Anticancer Res 2002; 22: 3285–92.
- 21 Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001; 3: 278–83.
- 22 Hattori Y, Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer with herpes simplex virus thymidine kinase and connexin 43. Cancer Gene Ther 2005; 12: 796–809.
- 23 Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51–9.
- 24 Pang S, Dannull J, Kaboo R et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997; 57: 495–9.
- 25 Hattori Y, Kubo H, Higashiyama K, Maitani Y. Folate-linked nanoparticles formed with DNA complexes in sodium chloride solution enhance transfection efficiency. J Biomed Nanotechnol 2005; 1: 176–84.
- 26 Rein DT, Breidenbach M, Nettelbeck DM et al. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med 2004; 6: 1281–9.
- 27
Good D,
Schwarzenberger P,
Eastham JA et al.
Cloning and characterization of the prostate-specific membrane antigen promoter.
J Cell Biochem
1999; 74: 395–405.
10.1002/(SICI)1097-4644(19990901)74:3<395::AID-JCB8>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 28 Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991; 51: 3748–52.
- 29 Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807–11.
- 30 Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 2002; 285: 247–56.
- 31 Watt F, Martorana A, Brookes DE et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001; 73: 243–54.
- 32 Zeng H, Wu Q, Li H et al. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl 2005; 26: 215–21.
- 33 Miyauchi M, Shimada H, Kadomatsu K et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 1999; 90: 469–75.
- 34 Matsubara S, Take M, Pedraza C, Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem (Tokyo) 1994; 115: 1088–96.
- 35 Pang S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther 2000; 7: 991–6.
- 36 Ellis WJ, Vessella RL, Buhler KR et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996; 2: 1039–48.
- 37 O’Keefe DS, Uchida A, Bacich DJ et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45: 149–57.
- 38 Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg 2002; 37: 588–92.
- 39 Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005; 435: 1–14.
- 40 Zhang L, Adams JY, Billick E et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002; 5: 223–32.
- 41 Sato M, Johnson M, Zhang L et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003; 8: 726–37.
- 42 Iyer M, Salazar FB, Lewis X et al. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 2004; 10: 545–52.
